REMS® works for the people standard bone screening leaves out.
Because REMS® is radiation-free and produces both density and quality data, it is clinically appropriate for populations that historically have had limited bone assessment options.
Pregnancy and postpartum
The only bone assessment safe during pregnancy. Establishes a maternal baseline before the largest bone draw of a woman's life.
Perimenopause and menopause
Bone loss accelerates significantly during the menopause transition. REMS® catches it earlier than standard screening protocols allow.
GLP-1 medication users
Rapid weight loss is associated with measurable bone density decline. A baseline assessment protects what the scale doesn't show.
Type 2 diabetes
Bone density alone underestimates fracture risk in diabetic patients. REMS® bone quality assessment is more accurate for this population.
Cancer therapy patients
Treatment-related bone loss is significant. Radiation-free monitoring is appropriate for patients already exposed to therapeutic radiation.
Long-term medication users
Glucocorticoids, proton pump inhibitors, aromatase inhibitors, and other medications affect bone over time. REMS® allows safe repeated monitoring.
Pre-surgical planning
Pre-operative bone assessment for joint replacement and spine surgery. Helps surgical teams plan and manage post-operative outcomes.
Active aging and athletes
Performance-oriented individuals tracking bone health alongside training load. Repeated safe monitoring supports long-term planning.
Family history of osteoporosis
Establishing a baseline before peak bone loss begins. The earlier the picture is known, the more can be done about it.
Ready when you are.
Book a complimentary appointment now; public scan events open mid-Summer 2026. Schedule yours, or if you're a provider or organization, bring REMS® to the people you serve.